Testing a new cancer drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer that cannot be removed or has spread, and standard treatment is not suitable
- You fit one of the study cancer groups (for example: melanoma, NSCLC, kidney cancer, liver cancer, stomach/GEJ, or colorectal cancer)
- Your cancer diagnosis must be confirmed by tumor sample testing (histology or cytology)
- You have at least one measurable tumor spot by imaging (scan shows something that can be followed)
- You can sign informed consent and have adequate body function (such as blood clotting for some groups)
- You haven’t had recent serious complications that would make immunotherapy-type side effects unsafe (see screening questions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.